î
îž
āļĨāđāļāļāļāļīāļ
î
Urogen Pharma Ltd
URGN17.000USD
-0.170-0.99%
āļāļīāļÂ 03/30, 16:00ïžETïžāļĢāļēāļāļēāļĨāđāļēāļāđāļē 15 āļāļēāļāļĩ
186.33MāļĄāļđāļĨāļāđāļēāļāļĨāļēāļ
āļāļēāļāļāļļāļP/E TTM
î
āļĢāļēāļĒāļĨāļ°āđāļāļĩāļĒāļāđāļāļīāđāļĄāđāļāļīāļĄāļāļāļ Urogen Pharma Ltd āļāļĢāļīāļĐāļąāļ
UroGen Pharma Ltd. Is an Israel-based biopharmaceutical company. The Company is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC).
āļāđāļāļĄāļđāļĨ Urogen Pharma Ltd
îāļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļURGN
āļāļ·āđāļāļāļĢāļīāļĐāļąāļUrogen Pharma Ltd
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļMay 04, 2017
āļāļĩāļāļĩāđāļBarrett (Elizabeth A)
āļāļģāļāļ§āļāļāļāļąāļāļāļēāļ235
āļāļĢāļ°āđāļ āļāļāļēāļĢāļĢāļąāļāļĐāļēāļāļ§āļēāļĄāļāļĨāļāļāļ āļąāļĒOrdinary Share
āļŠāļīāđāļāļāļĩāļāļāļāļĢāļ°āļĄāļēāļMay 04
āļāļĩāđāļāļĒāļđāđ9 Ha'ta'asiya St
āđāļĄāļ·āļāļRA'ANANA
āļāļĨāļēāļāļŦāļĨāļąāļāļāļĢāļąāļāļĒāđNASDAQ OMX - NASDAQ BASIC
āļāļĢāļ°āđāļāļĻIsrael
āļĢāļŦāļąāļŠāđāļāļĢāļĐāļāļĩāļĒāđ4365007
āđāļāļĢāļĻāļąāļāļāđ97297707601
āđāļ§āđāļāđāļāļāđhttps://www.urogen.com/
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļURGN
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļMay 04, 2017
āļāļĩāļāļĩāđāļBarrett (Elizabeth A)
āļāļđāđāļāļĢāļīāļŦāļēāļĢāļāļĢāļīāļĐāļąāļāļāļāļ Urogen Pharma Ltd
îāļāļ·āđāļ
āļāļ·āđāļ/āļāļģāđāļŦāļāđāļ
āļāļģāđāļŦāļāđāļ
āļāļēāļĢāļāļ·āļāļŦāļļāđāļ
āđāļāļĨāļĩāđāļĒāļ
Dr. Arie S. Belldegrun, M.D.
Dr. Arie S. Belldegrun, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
408.69K
--
Ms. Elizabeth A. (Liz) Barrett
Ms. Elizabeth A. (Liz) Barrett
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
326.69K
--
Mr. Jason Drew Smith
Mr. Jason Drew Smith
Chief Compliance Officer, General Counsel, Corporate Secretary
Chief Compliance Officer, General Counsel, Corporate Secretary
51.33K
-14.57%
Mr. Christopher (Chris) Degnan
Mr. Christopher (Chris) Degnan
Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer
Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer
2.28K
--
Ms. Cynthia M. Butitta
Ms. Cynthia M. Butitta
Independent Director
Independent Director
2.00K
--
Dr. Stuart Holden, M.D.
Dr. Stuart Holden, M.D.
Independent Director
Independent Director
--
--
Dr. Mark P. Schoenberg, M.D.
Dr. Mark P. Schoenberg, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Vincent Perrone
Mr. Vincent Perrone
Investor Relations
Investor Relations
--
--
Dr. Leana S. Wen, M.D.
Dr. Leana S. Wen, M.D.
Independent Director
Independent Director
--
--
Mr. Daniel G. Wildman
Mr. Daniel G. Wildman
Independent Director
Independent Director
--
--
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
āļāļ·āđāļ
āļāļ·āđāļ/āļāļģāđāļŦāļāđāļ
āļāļģāđāļŦāļāđāļ
āļāļēāļĢāļāļ·āļāļŦāļļāđāļ
āđāļāļĨāļĩāđāļĒāļ
Dr. Arie S. Belldegrun, M.D.
Dr. Arie S. Belldegrun, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
408.69K
--
Ms. Elizabeth A. (Liz) Barrett
Ms. Elizabeth A. (Liz) Barrett
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
326.69K
--
Mr. Jason Drew Smith
Mr. Jason Drew Smith
Chief Compliance Officer, General Counsel, Corporate Secretary
Chief Compliance Officer, General Counsel, Corporate Secretary
51.33K
-14.57%
Mr. Christopher (Chris) Degnan
Mr. Christopher (Chris) Degnan
Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer
Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer
2.28K
--
Ms. Cynthia M. Butitta
Ms. Cynthia M. Butitta
Independent Director
Independent Director
2.00K
--
Dr. Stuart Holden, M.D.
Dr. Stuart Holden, M.D.
Independent Director
Independent Director
--
--
āļŠāļąāļāļŠāđāļ§āļāļāļāļāļĢāļēāļĒāđāļāđ
āļŠāļāļļāļĨāđāļāļīāļ: USDāļāļąāļāđāļāļāđāļĄāļ·āđāļ: āļ§āļąāļāļāļąāļāļāļēāļĢāļāļĩāđ 6 āļĄ.āļ.
āļŠāļāļļāļĨāđāļāļīāļ: USDāļāļąāļāđāļāļāđāļĄāļ·āđāļ: āļ§āļąāļāļāļąāļāļāļēāļĢāļāļĩāđ 6 āļĄ.āļ.
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
āļāļēāļĄāļāļļāļĢāļāļīāļUSD
āļāļ·āđāļ
āļĢāļēāļĒāđāļāđ
āļŠāļąāļāļŠāđāļ§āļ
Jelmyto
25.70M
93.53%
Zusduri
1.78M
6.47%
āļāđāļāļĄāļđāļĨāļāļĩāđāđāļāļĩāđāļĒāļ§āļāđāļāļāļĒāļąāļāđāļĄāđāđāļāđāļĢāļąāļāļāļēāļĢāđāļāļīāļāđāļāļĒāļāļēāļāļāļēāļāļāļĢāļīāļĐāļąāļ
āļāļēāļĄāļāļļāļĢāļāļīāļ
āļāļēāļĄāļ āļđāļĄāļīāļ āļēāļ
āļāļēāļĄāļāļļāļĢāļāļīāļUSD
āļāļ·āđāļ
āļĢāļēāļĒāđāļāđ
āļŠāļąāļāļŠāđāļ§āļ
Jelmyto
25.70M
93.53%
Zusduri
1.78M
6.47%
āļŠāļāļīāļāļīāļāļēāļĢāļāļ·āļāļŦāļļāđāļ
āļāļąāļāđāļāļāđāļĄāļ·āđāļ: āļ§āļąāļāļāļĪāļŦāļąāļŠāļāļĩāđ 19 āļ.āļ.
āļāļąāļāđāļāļāđāļĄāļ·āđāļ: āļ§āļąāļāļāļĪāļŦāļąāļŠāļāļĩāđ 19 āļ.āļ.
āļāļđāđāļāļ·āļāļŦāļļāđāļ
āļāļĢāļ°āđāļ āļāļāļđāđāļāļ·āļāļŦāļļāđāļ
āļāļđāđāļāļ·āļāļŦāļļāđāļ
āļāļđāđāļāļ·āļāļŦāļļāđāļ
āļŠāļąāļāļŠāđāļ§āļ
RTW Investments L.P.
9.33%
Paradigm BioCapital Advisors LP
9.19%
Morgan Stanley & Co. LLC
5.13%
Jefferies LLC
4.52%
BlackRock Institutional Trust Company, N.A.
4.50%
āļāļ·āđāļ āđ
67.33%
āļāļđāđāļāļ·āļāļŦāļļāđāļ
āļāļđāđāļāļ·āļāļŦāļļāđāļ
āļŠāļąāļāļŠāđāļ§āļ
RTW Investments L.P.
9.33%
Paradigm BioCapital Advisors LP
9.19%
Morgan Stanley & Co. LLC
5.13%
Jefferies LLC
4.52%
BlackRock Institutional Trust Company, N.A.
4.50%
āļāļ·āđāļ āđ
67.33%
āļāļĢāļ°āđāļ āļāļāļđāđāļāļ·āļāļŦāļļāđāļ
āļāļđāđāļāļ·āļāļŦāļļāđāļ
āļŠāļąāļāļŠāđāļ§āļ
Investment Advisor
25.32%
Hedge Fund
24.32%
Investment Advisor/Hedge Fund
21.57%
Research Firm
13.54%
Insurance Company
3.98%
Pension Fund
2.38%
Individual Investor
2.02%
Private Equity
1.80%
Corporation
1.72%
āļāļ·āđāļ āđ
3.35%
āļāļēāļĢāļāļ·āļāļŦāļļāđāļāļāļāļāļŠāļāļēāļāļąāļ
îāļāļąāļāđāļāļāđāļĄāļ·āđāļ: āļ§āļąāļāļāļĪāļŦāļąāļŠāļāļĩāđ 1 āļĄ.āļ.
āļāļąāļāđāļāļāđāļĄāļ·āđāļ: āļ§āļąāļāļāļĪāļŦāļąāļŠāļāļĩāđ 1 āļĄ.āļ.
āļāđāļ§āļāđāļ§āļĨāļēāļāļēāļĢāļĢāļēāļĒāļāļēāļ
āļāļģāļāļ§āļāļŠāļāļēāļāļąāļ
āļŦāļļāđāļāļāļĩāđāļāļ·āļāļāļĢāļāļ
āļŠāļąāļāļŠāđāļ§āļ
āđāļāļĨāļĩāđāļĒāļ
2025Q4
321
48.31M
103.21%
-13.86M
2025Q3
311
45.66M
97.55%
-6.58M
2025Q2
285
53.00M
114.72%
+5.27M
2025Q1
290
49.25M
108.64%
+1.67M
2024Q4
280
43.94M
103.24%
-1.94M
2024Q3
262
44.13M
104.63%
-2.19M
2024Q2
247
46.02M
111.40%
+11.07M
2024Q1
255
34.96M
99.86%
+5.57M
2023Q4
237
29.16M
94.80%
+4.33M
2023Q3
238
25.93M
86.41%
+2.69M
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
āļāļīāļāļāļĢāļĢāļĄāļāļđāđāļāļ·āļāļŦāļļāđāļ
îāļāļ·āđāļ
āļŦāļļāđāļāļāļĩāđāļāļ·āļāļāļĢāļāļ
āļŠāļąāļāļŠāđāļ§āļ
āđāļāļĨāļĩāđāļĒāļ
āđāļāļĨāļĩāđāļĒāļ%
āļ§āļąāļāļāļĩāđ
RTW Investments L.P.
4.54M
9.71%
--
--
Sep 30, 2025
Paradigm BioCapital Advisors LP
4.22M
9.01%
+1.88M
+80.79%
Sep 30, 2025
Morgan Stanley & Co. LLC
2.46M
5.25%
+983.01K
+66.65%
Sep 30, 2025
Jefferies LLC
2.20M
4.7%
--
--
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
2.14M
4.58%
+33.75K
+1.60%
Sep 30, 2025
SilverArc Capital Management, LLC
1.58M
3.37%
-445.20K
-22.01%
Sep 30, 2025
Acorn Capital Advisors, LLC
1.26M
2.69%
--
--
Sep 30, 2025
UBS Asset Management Switzerland AG
1.32M
2.82%
--
--
Jan 31, 2025
SG Americas Securities, L.L.C.
1.16M
2.47%
+8.30K
+0.72%
Sep 30, 2025
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
ETF āļāļĩāđāđāļāļĩāđāļĒāļ§āļāđāļāļ
îāļāļąāļāđāļāļāđāļĄāļ·āđāļ: āļ§āļąāļāđāļŠāļēāļĢāđāļāļĩāđ 6 āļ.āļ.
āļāļąāļāđāļāļāđāļĄāļ·āđāļ: āļ§āļąāļāđāļŠāļēāļĢāđāļāļĩāđ 6 āļ.āļ.
āļāļ·āđāļ
āļŠāļąāļāļŠāđāļ§āļ
ARK Israel Innovative Technology ETF
2.09%
Tema Oncology ETF
1.92%
ALPS Medical Breakthroughs ETF
0.39%
Hypatia Women CEO ETF
0.28%
ProShares Ultra Nasdaq Biotechnology
0.16%
iShares Micro-Cap ETF
0.15%
Fidelity Enhanced Small Cap ETF
0.11%
Vanguard US Momentum Factor ETF
0.1%
Invesco Nasdaq Biotechnology ETF
0.09%
iShares Biotechnology ETF
0.07%
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
ARK Israel Innovative Technology ETF
āļŠāļąāļāļŠāđāļ§āļ2.09%
Tema Oncology ETF
āļŠāļąāļāļŠāđāļ§āļ1.92%
ALPS Medical Breakthroughs ETF
āļŠāļąāļāļŠāđāļ§āļ0.39%
Hypatia Women CEO ETF
āļŠāļąāļāļŠāđāļ§āļ0.28%
ProShares Ultra Nasdaq Biotechnology
āļŠāļąāļāļŠāđāļ§āļ0.16%
iShares Micro-Cap ETF
āļŠāļąāļāļŠāđāļ§āļ0.15%
Fidelity Enhanced Small Cap ETF
āļŠāļąāļāļŠāđāļ§āļ0.11%
Vanguard US Momentum Factor ETF
āļŠāļąāļāļŠāđāļ§āļ0.1%
Invesco Nasdaq Biotechnology ETF
āļŠāļąāļāļŠāđāļ§āļ0.09%
iShares Biotechnology ETF
āļŠāļąāļāļŠāđāļ§āļ0.07%
āđāļāļīāļāļāļąāļāļāļĨ
îāļĄāļĩāļāļēāļĢāļāđāļēāļĒāđāļāļīāļāļāļąāļāļāļĨāđāļāđāļāļāļģāļāļ§āļāļĢāļ§āļĄ
0.00
USD āđāļāļāđāļ§āļ 5 āļāļĩāļāļĩāđāļāđāļēāļāļĄāļē
āļ§āļąāļāļāļĩāđ
āđāļāļīāļāļāļąāļāļāļĨ
āļ§āļąāļāļāļĩāđāļāļąāļāļāļķāļ
āļ§āļąāļāļāļĩāđāļāļģāļĢāļ°āđāļāļīāļ
āļ§āļąāļāļāļĩāđāđāļĄāđāđāļāđāļĢāļąāļāļŠāļīāļāļāļīāļāļąāļāļāļĨ
āđāļĄāđāļĄāļĩāļāđāļāļĄāļđāļĨ
āļāļēāļĢāđāļāđāļāļŦāļļāđāļ
îāļ§āļąāļāļāļĩāđ
āļ§āļąāļāļāļĩāđāđāļĄāđāđāļāđāļĢāļąāļāļŠāļīāļāļāļīāļāļąāļāļāļĨ
āļāļĢāļ°āđāļ āļ
āļāļąāļāļĢāļēāļŠāđāļ§āļ
āđāļĄāđāļĄāļĩāļāđāļāļĄāļđāļĨ
āļ§āļąāļāļāļĩāđ
āļ§āļąāļāļāļĩāđāđāļĄāđāđāļāđāļĢāļąāļāļŠāļīāļāļāļīāļāļąāļāļāļĨ
āļāļĢāļ°āđāļ āļ
āļāļąāļāļĢāļēāļŠāđāļ§āļ
āđāļĄāđāļĄāļĩāļāđāļāļĄāļđāļĨ
